Asymmetrex Will Present Its New Contract Service For Counting Adult Tissue Stem Cells at Three Fall Conferences
Boston (PRWEB) August 23, 2016 -- At its company website, Asymmetrex has reported data showing its success in determining the number of stem cells from three different types of human tissues, including bone marrow, liver, and lungs. The stem cell counting technology is based on computer simulation analyses of basic cell count data. Recent refinements in the software allow Asymmetrex to also determine tissue stem cell number using published cell count data from human tissue cell cultures. This new capability will allow the company to rapidly increase its experience with counting stem cells in many different human tissues. Most recently, this approach has been used to estimate the number of tissue stem cells in amniotic fluid cell preparations for first time.
The AlphaSTEM Test is also a powerful new tool for the pharmaceutical industry. Now being able to monitor the effects of drug candidates on stem cell number and function, it is possible to identify stem cell-toxic drugs in relatively inexpensive cell culture formats. Stem cell-toxic drugs cause chronic organ failure in animals and people. The new Asymmetrex service can provide significant savings to pharmaceutical companies by earlier identification of stem cell-toxic drugs that will fail later in animal studies and clinical trials, which are much more expensive. Estimates suggest that such failures cost the U.S. pharmaceutical industry 4 to 5 billion dollars each year.
This fall, Asymmetrex will introduce its new stem cell counting contract service to important industry audiences in three different conference forums. Two of the conferences will take place in Boston. The third is a global web-based conference. The web conference, organized by Euroscicon Life Sciences Events, addresses “Moving Forward With Stem Cell Therapy.” Scheduled for September 6-8, it is the first live-streamed only, three day professional conference to discuss cellular therapies. Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., will discuss how the ability to count tissue stem cells will change forever the practice of stem cell medicine and tissue stem cell research.
Director Sherley will give a second presentation at BioPharm America 2016 that occurs September 13-15. In addition, to giving a talk on the new AlphaSTEM Test service, he has invited representatives from more than 70 pharmaceutical companies to join him in one-on-one meetings to learn about the new technology and how it can significantly improve their bottom lines each year.
A third presentation will be made at a new addition to the clinical trials conference landscape. The Arena International 1st Annual Preclinical Development Operations Summit will take place in Boston November 15-16. In addition to introducing Asymmetrex’s new tissue stem counting contract service, Director Sherley will discuss how beginning now to implement stem cell counting procedures in preclinical development operations for regenerative medicine will prepare companies for an inevitable future of the FDA mandating stem cell dosing data.
“Asymmetrex has the good fortune of having developed a technology whose time is now.” Director Sherley refers to current increased attention to some new and some longstanding challenges in stem cell medicine. The FDA is under increasing pressure to do something about now hundreds, and maybe thousands, of stem cell treatment clinics that inject patients without knowing the number or quality of stem cells. However, FDA-approved clinical trials are allowed to proceed, even though they also lack the same crucial information. The National Institute of Standards and Technology (NIST) recently launched a program to develop new technologies for standardizing cell measurements. First in the U.K. and now in the U.S., there are new initiatives by drug regulation agencies to reduce the number of animals used for drug evaluations. Worldwide there are many hundreds of thousands of banked umbilical cord blood samples that contain blood stem cells needed to treat diseases like childhood leukemia; but there is no method in use to determine the stem cell potency of these potentially life saving cells.
In the scheduled fall forums, Director Sherley will discuss with these three diverse industry audiences how Asymmetrex’s new AlphaSTEM Test contract service is the solution for each of these challenges, which they currently face daily.
About Asymmetrex
Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.
James L. Sherley, M.D., Ph.D., Asymmetrex, LLC, http://asymmetrex.com, +1 (617) 990-6819, [email protected]
Share this article